San Francisco, CA ; 03/18/2020
Amount Funded: $120 Million
Lead Investor: Foresite Capital
Participating Investor(s): Bain Capital Life Sciences, Boxer Captial, EcoR1 Capital, Redmile Group, Third Rock Ventures, The Column Group, Wellington Management Company, others.
Company Description: Nurix Therapeutics develops novel therapies that modulate protein levels through small molecule drugs targeting E3 ligases. Nurix’s pipeline is focused on developing drugs for immune-mediated diseases and hematologic cancers including immuno-oncology therapeutics. Nurix was founded by internationally recognized experts in E3 ligase biology and immunology and is funded by leading life science investors and corporate partners.
What funding will be used for: Advancing its wholly owned development candidates into clinical development.
“With the funds raised in this financing, Nurix is well positioned to bring its targeted protein modulation therapeutics into the clinic. We will also continue to use our powerful DELigase™ platform to discover new therapies aimed at previously undruggable targets of high therapeutic potential.”
-Arthur Sands, M.D., Ph. D, CEO, Nurix Therapeutics
“Nurix’s CTM and DELigaseTM platform technologies have led to the discovery of novel BTK degraders with the potential to transform the treatment landscape for hematological indications. Their differentiated platform and novel approach have resulted in strategic corporate partnerships and we believe position the company as a leader in the emerging protein modulation field.”
-Michael Rome, Ph.D., Partner, Foresite Capital
Data provided by respective company (unless otherwise noted) and researched by StartupsOne for accuracy.